This article first appeared on GuruFocus.

Fourth Quarter Revenue: $159 million, up 6% year-over-year on a reported basis, and up 4% organically.

Fiscal Year 2025 Revenue: $594 million, up 4% on a reported basis, and up 3% organically.

Non-GAAP EPS (Q4): $0.21.

Non-GAAP EPS (Full Year): $0.51.

Adjusted EBITDA Margin (Q4): 13%.

Adjusted EBITDA Margin (Full Year): 11.2%, representing an expansion of 310 basis points.

Free Cash Flow (Q4): Usage of $6 million.

Free Cash Flow (Full Year): $38 million, an improvement of $26 million year-over-year.

Cash, Cash Equivalents, and Marketable Securities: $546 million.

Multi-Omics Revenue (Q4): $73 million, 11% growth on a reported basis and 10% organic growth.

Sample Management Solutions Revenue (Q4): $86 million, up 2% reported and flat organically.

Non-GAAP Gross Margin (Q4): 46.7%, down 20 basis points year-over-year.

Guidance for Fiscal 2026: Organic revenue growth of 3% to 5%, with adjusted EBITDA margin expansion of 300 basis points.

Warning! GuruFocus has detected 2 Warning Sign with AZTA.

Is AZTA fairly valued? Test your thesis with our free DCF calculator.

Release Date: November 21, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Azenta Inc (NASDAQ:AZTA) achieved 3% core growth and delivered meaningful margin expansion of 310 basis points in fiscal 2025.

The company has a strong balance sheet with over $0.5 billion in cash, cash equivalents, and marketable securities, providing financial flexibility.

Azenta Inc (NASDAQ:AZTA) implemented the Azenta Business System (ABS), leading to measurable improvements in quality, on-time delivery, and overall productivity.

The Multi-Omics segment delivered a record quarter with 11% growth on a reported basis and 10% organic growth.

Azenta Inc (NASDAQ:AZTA) is well-positioned to capitalize on outsourcing trends and automation, areas where the company is a leader.

The macroeconomic environment remains challenging, with softer academic and NIH funding and ongoing geopolitical uncertainty impacting growth.

Azenta Inc (NASDAQ:AZTA) experienced a decline in Sanger sequencing revenue, which fell by low double digits year-over-year.

The company anticipates a slower start in fiscal 2026, with first-quarter revenue expected to decline approximately 1% to 2% year-over-year.

Capital expenditures in stores and cryogenic solutions are impacted by ongoing customer budget constraints and macroeconomic uncertainty.

The government shutdown caused delays in new grant reviews and approvals, affecting bookings and pushing some revenue into future quarters.

Q: Can you elaborate on the guidance for 3% to 5% growth and the expected decline in the fiscal first quarter? A: John Marotta, CEO, explained that the slowdown in capital expenditures, particularly affecting stores and cryo, is impacting growth. The government shutdown also contributed to guidance adjustments. The market is expected to grow at 1% to 2%, and Azenta aims to outperform this. Lawrence Lin, CFO, added that the macro slowdown and government funding issues are significant factors, with the first quarter expected to see a decline due to these challenges.

Q: What is driving your confidence in mid-single-digit growth for Sample Management Solutions (SMS)? A: Lawrence Lin, CFO, highlighted that investments in commercial leadership and a new pricing strategy are expected to drive growth. The company has closed significant deals in manufactured and bulk compounds, which supports their confidence in achieving mid-single-digit growth in SMS.

Q: How is the macroeconomic backdrop affecting your customer base, particularly in capital equipment? A: John Marotta, CEO, noted strength in pharma spending, with some projects in pharma and biotech being repositioned. The academic and government sectors have slowed due to the government shutdown, but overall, pharma remains a strong area for Azenta.

Q: Can you provide more details on the Multi-Omics segment's low single-digit growth expectation? A: John Marotta, CEO, mentioned that normalization in next-generation sequencing (NGS) is a key factor. Lawrence Lin, CFO, added that while NGS saw double-digit growth in fiscal 2025, it is expected to normalize to mid-single-digit growth in fiscal 2026.

Q: How are you approaching M&A and what areas are you focusing on for potential acquisitions? A: John Marotta, CEO, stated that the focus is on tuck-in acquisitions to expand core businesses, particularly in Sample Repository Solutions (SRS), automated solutions, and synthesis. The company aims to execute on these opportunities in fiscal 2026, following a foundational reset in fiscal 2025.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.